An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-03382792 In Healthy Elderly Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs PF 3382792 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 06 Jul 2010 Trial status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 May 2010 Planned end date changed from 1 Jun 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 12 May 2010 Planned initiation date changed from 1 Apr 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.